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Abstract: AIMS Neprilysin (NEP), a zinc metallopeptidase, degrades a variety of bioactive peptides in-
cluding natriuretic peptides terminating their biological action on arterial blood pressure and natriuresis.
Pharmacological inhibition of NEP reduces mortality in patients with heart failure with reduced ejection
fraction. Physiological interventions reducing NEP levels are unknown in humans. Because obesity leads
to increased NEP levels and increases the risk for heart failure, we hypothesized that weight loss reduces
NEP concentrations in plasma and tissue. METHODS AND RESULTS We randomized overweight to
obese human subjects to a low-fat or low-carbohydrate hypocaloric 6 month weight loss intervention. Sol-
uble NEP was determined in plasma, and NEP mRNA was analysed from subcutaneous adipose tissue
before and after diet. Low-fat diet-induced weight loss reduced soluble NEP levels from 0.83 ± 0.18 to
0.72 ± 0.18 ฀g/L (P = 0.038), while subcutaneous adipose tissue NEP mRNA expression was reduced by
both dietary interventions [21% (P = 0.0057) by low-fat diet and 16% (P = 0.048) by low-carbohydrate
diet]. We also analysed the polymorphisms of the gene coding for NEP, rs9827586 and rs701109, known
to be associated with plasma NEP levels. For both single-nucleotide polymorphisms, minor allele carriers
(A/A) had higher baseline plasma NEP levels (rs9827586: ฀ = 0.53 ± 0.23, P < 0.0001; rs701109: ฀ = 0.43
± 0.22, P = 0.0016), and minor allele carriers of rs9827586 responded to weight loss with a larger NEP
reduction (rs9827586: P = 0.0048). CONCLUSIONS Our study identifies weight loss via a hypocaloric
low-fat diet as the first physiological intervention in humans to reduce NEP in plasma and adipose tissue.
Specific single-nucleotide polymorphisms further contribute to the decrease. Our findings may help to
explain the beneficial effect of weight loss on cardiac function in patients with heart failure.
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Abstract
Aims Neprilysin (NEP), a zinc metallopeptidase, degrades a variety of bioactive peptides including natriuretic peptides ter-
minating their biological action on arterial blood pressure and natriuresis. Pharmacological inhibition of NEP reduces mortality
in patients with heart failure with reduced ejection fraction. Physiological interventions reducing NEP levels are unknown in
humans. Because obesity leads to increased NEP levels and increases the risk for heart failure, we hypothesized that weight
loss reduces NEP concentrations in plasma and tissue.
Methods and results We randomized overweight to obese human subjects to a low-fat or low-carbohydrate hypocaloric
6 month weight loss intervention. Soluble NEP was determined in plasma, and NEP mRNA was analysed from subcutaneous
adipose tissue before and after diet. Low-fat diet-induced weight loss reduced soluble NEP levels from 0.83 ± 0.18 to
0.72 ± 0.18 μg/L (P = 0.038), while subcutaneous adipose tissue NEP mRNA expression was reduced by both dietary interven-
tions [21% (P = 0.0057) by low-fat diet and 16% (P = 0.048) by low-carbohydrate diet]. We also analysed the polymorphisms of
the gene coding for NEP, rs9827586 and rs701109, known to be associated with plasma NEP levels. For both single-nucleotide
polymorphisms, minor allele carriers (A/A) had higher baseline plasma NEP levels (rs9827586: β = 0.53 ± 0.23, P < 0.0001;
rs701109: β = 0.43 ± 0.22, P = 0.0016), and minor allele carriers of rs9827586 responded to weight loss with a larger NEP re-
duction (rs9827586: P = 0.0048).
Conclusions Our study identifies weight loss via a hypocaloric low-fat diet as the first physiological intervention in humans to
reduce NEP in plasma and adipose tissue. Specific single-nucleotide polymorphisms further contribute to the decrease. Our
findings may help to explain the beneficial effect of weight loss on cardiac function in patients with heart failure.
Keywords Neprilysin; Hypocaloric low-fat diet; Natriuretic peptides; Heart failure
Received: 30 March 2020; Revised: 4 October 2020; Accepted: 6 January 2021
*Correspondence to: Andreas L. Birkenfeld, Section of Internal Medicine IV, Department of Diabetology, Endocrinology and Nephrology, University Hospital Tübingen,
Ottfriet-Müller-Str. 10, 72076 Tübingen, Germany. Tel: +49-7071 29-82735; Fax: +49-7071 29-2784. Email: andreas.birkenfeld@med.uni-tuebingen.de
Background
Numbers of patients with heart failure (HF) are dramatically
increasing with 26 million people affected worldwide. Once
patients are diagnosed, the mortality rate is high with 50%
dying within 5 years.1 Research on proteins and mechanisms
involved in HF are therefore of big interest. One interesting
enzyme in the field is neprilysin (NEP), a zinc-dependent
membrane metallopeptidase located on the cell surface,
which inactivates several bioactive peptides, such as natri-
uretic peptides (NPs).2–4 Atrial NP and brain NP are synthe-
sized as pre-prohormones in the heart, regulating arterial
blood pressure in an endocrine fashion by inhibiting renal so-
dium reabsorption, suppressing aldosterone secretion from
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the adrenals, and a direct vasodilatory effect.5–7 Therefore,
NP clearance by NEP is of high clinical relevance.
Neprilysin is mainly synthesized in adipose tissue and can
be separated from the cell surface to circulate in a soluble,
catalytic active form in the blood stream.8 Pharmacological
inhibition of NEP leads to enhanced diuresis and natriuresis,5
likely because the degradation of NPs is inhibited. Accord-
ingly, the combined renin–angiotensin system and NEP inhib-
itor LCZ693 (sacubitril and valsartan)9 conveys important
clinical benefit in patients with HF with reduced ejection
fraction.
The development and progression of HF is highly linked to
obesity as HF is slowed down by maintaining low body fat
and high insulin sensitivity.10 Interestingly, combined renin–
angiotensin system and NEP inhibitors also improve insulin
sensitivity in obese individuals and glucose control in patients
with diabetes.11,12 Together, these data highlight the role of
NEP inhibition in cardiovascular—but also metabolic disease.
So far, clinical data on the interaction between dietary inter-
ventions and NEP concentrations or activity are missing in
humans. Our study aimed at determining how low-calorie–
low-carbohydrate and low-calorie–low-fat diets affect NEP
plasma levels.
Aims
Primarily, we assessed for the first time soluble plasma NEP
levels and adipose tissue NEP RNA expression from obese pa-
tients before and after weight reduction due to two
hypocaloric diet regimens. Secondarily, we also tested if the
two single-nucleotide polymorphisms (SNPs) rs9827586 and
rs701109 in the NEP locus, which have been reported to be
associated with changed NEP levels,13 affect NEP regulation
in these subjects.
Material and methods
We included overweight and obese but otherwise healthy in-
dividuals (52 women and 10 men) of the B-SMART study
(ClinicalTrials.gov identifier: NCT00956566). Data were gener-
ated in a prospective, randomized manner comparing weight
reduction by either a hypocaloric low-carbohydrate or low-fat
diet over a 6 month intervention period.14 Details can
be found in Haufe et al.14 All anthropometric and
cardio-metabolic outcomes presented here were measured
as previously described. Body fat content was assessed by
nuclear magnetic resonance.14,15 Additionally, circulating
soluble NEP as well as other cardiovascular and metabolic
measurements were obtained at baseline and after 6 month
dietary weight loss. Soluble NEP in plasma samples was de-
termined with a Solid Phase Sandwich ELISA (R&D Systems,
Minneapolis, MN, USA), and NEP gene expression in subcuta-
neous adipose tissue (SAT) samples was obtained by needle
biopsies as described.16 NEP mRNA expression was measured
with SYBR Green (Thermo Fisher Scientific, Wilmington, DE,
USA) and was normalized to relative expression of HPRT.
DNA from 62 patients was isolated from whole blood using
a commercial DNA isolation kit, and SNP genotyping was per-
formed based on Ilumina Human610-Quadv1. Data were
analysed with the GenomeStudio Genotyping from Ilumina.
For both SNPs, the minor allele showed a frequency of
15.6% [rs9827586: 15.6% (AA), 54.4% (AG), and 30% (GG);
rs701109: 15.6% (AA), 51.1% (AG), and 33.3% (GG)].
All statistical analyses were performed with SPSS 18 (SPSS,
Inc., Chicago, IL, USA) or JMP 13.0 (SAS, Institute Cary, NC,
USA). Univariate associations between ∆NEP and ∆body
weight were tested using Pearson correlation. To test differ-
ences of clinical characteristics between NEP tertiles at base-
line or ∆NEP, we used one-way ANOVA with Bonferroni’s
post hoc test without and with Bonferroni–Holm correction
for multiple testing. To test for interactions between diet
groups over 6 month period (diet × time), we used a
two-way ANOVA for repeated measurements. Within-group
differences in response to 6 month diet were analysed using
paired two-tailed t-tests. The association of genetic variation
in the NEP locus with circulating NEP concentrations was
tested by multiple linear regression analyses under an addi-
tive inheritance model. NEP concentrations and age were
log-transformed prior to analysis to approximate normal dis-
tribution. Significance was assumed when P ≤ 0.05.
Results
Participants were divided into low (n = 21), middle (n = 21),
and high tertiles (n = 20) of baseline NEP plasma concentra-
tions. High NEP levels were associated with high
intramyocellular fat, end-diastolic volume index, VO2 max,
pericardial fat, and trend with higher fat mass (P = 0.07)
(Table 1). After correction for multiple testing, only VO2
max remained associated with NEP levels at baseline
(Table 1). Other baseline data and clinical outcomes for both
diet interventions were previously reported in detail.14,15
Overall, after 6 months of the hypocaloric diet interven-
tion, patients on a low-carbohydrate diet (n = 26; 2 male
and 24 female, age: 42.5 ± 9.1 years) lost 7.02 ± 4.21 kg,
and patients on a low-fat diet (n = 36; 8 male and 28 female,
age: 47.5 ± 8.7 years) lost 6.66 ± 4.4 kg of body weight.
Weight loss was similar in tertiles according to NEP baseline
concentration (low: 6.2 ± 4.1 kg; middle: 7.6 ± 4.2 kg; and
high: 9.5 ± 4.6 kg; between tertiles P = 0.472). When combin-
ing both dietary inventions, NEP levels before and after diet
did not change (Figure 1A). Yet, when analysing the low-fat-
diet intervention separately, we observed a decrease of
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plasma NEP levels from 0.83 ± 0.18 to 0.72 ± 0.18 μg/L
(n = 36; P = 0.038, Figure 1B) during the study, whereas in
the low-carbohydrate diet group, the reduction in NEP levels
was not significantly reduced (1.23 ± 0.34 to 1.04 ± 0.25 μg/L,
n = 26; P = 0.373). Correlation analysis between decrease in
NEP with the decrease in body weight resulted in a positive
association between both parameters (r = 0.239; P = 0.062).
SAT mRNA expression of NEP was markedly reduced by 21%
by the low-fat diet (1 ± 0.086 to 0.799 ± 0.057, n = 34;
P = 0.0057) and by 16% by the low-carbohydrate diet
(1 ± 0.079 to 0.847 ± 0.045, n = 29; P = 0.048) (Figure 1C).
Changes in NEP plasma levels and mRNA levels between
the two diet groups over time did not differ significantly
(time × diet: NEPplasma, P = 0.671; NEPmRNAexpression,
P = 0.336). We next analysed the contribution of changes in
soluble NEP to improvement of clinical characteristics and
the contribution of clinical characteristics at baseline for
changes in soluble NEP. Dividing NEP changes in tertiles (high
reduction, no reduction, and increase), we observed associa-
tions between ∆NEP and food habits at baseline. Larger











NEP (ng/mL) 0.21 ± 0.14 0.60 ± 0.12 2.26 ± 1.94 0.103 Ns
N (men/women) 4/17 2/19 4/16 0.62 Ns
Age (years) 48 ± 8 45 ± 8 42 ± 10 0.15 Ns
Body weight (kg) 94.1 ± 17.1 90.2 ± 16.7 86.7 ± 13.2 0.34 Ns
BMI (kg/m
2
) 33 ± 3 32.7 ± 4.4 31.5 ± 3.8 0.26 Ns
FM (%) 37.4 ± 3.8 35.1 ± 6.0 33.5 ± 5.8
a
0.07 Ns
Abdominal subcutaneous fat (kg) 10.5 ± 2.7 9.3 ± 2.6 8.6 ± 2.8 0.11 Ns
Abdominal visceral fat (kg) 2.1 ± 0.8 1.6 ± 0.6 1.7 ± 1.4 0.20 Ns
Intrahepatic fat content (%) 10.6 ± 11.9 7.2 ± 6.4 8.8 ± 12.2 0.59 Ns
Intramyocellular lipid content
[IMCL (creatine)]




Fasting glucose (mg/dL) 96.1 ± 8.3 99.8 ± 8.5 93.7 ± 8.2
b
0.08 Ns
Fasting insulin (U/mL) 6.7 ± 3.8 8.5 ± 5.9 6.0 ± 3.4 0.18 Ns
Glucose at 2 h OGTT (mg/dL) 129.7 ± 33.2 147.4 ± 37.8 140.1 ± 38.7 0.31 Ns
HOMA-IR (arbitrary unit) 1.6 ± 1.0 2.0 ± 1.3 1.4 ± 0.9 0.19 Ns
Cardiovascular parameter Ns
RR 24 h sys V0 (mm/Hg) 120.1 ± 11.5 120.2 ± 10.2 117.3 ± 6.8 0.59 Ns
RR 24 h dia V0 (mm/Hg) 72.4 ± 9.1 73.5 ± 6.8 72.6 ± 5.6 0.88 Ns
LV mass index (g/m) 41.7 ± 5.9 45.8 ± 7.8 46.7 ± 7.1
a
0.06 Ns
Ejection fraction (%) 62.0 ± 4.7 61.9 ± 5.6 59.1 ± 6.0 0.17 Ns
EDV index (mL/m
2
) 74.4 ± 11.7 75.5 ± 10.2 80.5 ± 8.0 0.13 Ns
ESV index (mL/m
2
) 28.5 ± 6.7 28.8 ± 6.0 33.0 ± 6.3
a
0.05* Ns
Cardiac output (L/min) 6248.0 ± 1079.4 6326.8 ± 1013.4 6925.5 ± 1387.6 0.15 Ns
Stroke volume (mL) 95.5 ± 21.1 98.0 ± 27.0 94.7 ± 16.4 0.88 Ns
Myocardial fat (mm) 0.7 ± 0.3 0.7 ± 0.2 0.7 ± 0.3 0.89 Ns
Epicardial fat (mm) 6.4 ± 2.7 6.3 ± 2.7 5.3 ± 3.2 0.56 Ns
Pericardial fat (mm) 29.2 ± 14.1 18.7 ± 5.4
a
21.6 ± 12.6 0.03* Ns
PFRE/PFRA ratio 1.4 ± 0.4 1.4 ± 0.4 1.5 ± 0.5 0.68 Ns
Cardiorespiratory fitness
VO2 max (mL/min/kg) 18.8 ± 3.5 24.1 ± 4.6
a
23.2 ± 5.0 <0.001* 0.017
Free fatty acids (mmol/L) 0.6 ± 0.2 0.6 ± 0.2 0.6 ± 0.2 0.49 Ns
Triglyceride (mmol/L) 1.0 ± 0.4 1.2 ± 0.5 1.2 ± 0.7 0.48 Ns
HDL (mmol/L) 1.4 ± 0.4 1.4 ± 0.3 1.5 ± 0.8 0.71 Ns
LDL (mmol/L) 3.2 ± 0.8 2.9 ± 0.8 2.9 ± 0.8 0.44 Ns
Total adiponectin (μg/mL) 6.2 ± 1.7 6.0 ± 2.4 5.7 ± 1.9 0.78 Ns
CRP (μg/mL) 1.9 ± 1.0 1.3 ± 0.8 1.2 ± 0.9 0.11 Ns
FABP4 (ng/mL) 34.6 ± 10.3 31.9 ± 10.1 32.0 ± 14.8 0.71 Ns
Leptin (ng/mL) 32.8 ± 10.6 34.7 ± 13.2 27.4 ± 14.7 0.27 Ns
mr-proANP (pmol/L) 59.8 ± 31.8 56.9 ± 22.6 46.5 ± 20.0 0.46 Ns
BMI, body mass index; CRP, C-reactive protein; dia, diastolic; EDV, end-diastolic volume; ESV, end-systolic volume; FABP4, fatty
acid-binding protein 4; FM, fat mass; HDL, high-density lipoprotein; HOMA-IR, Homeostasis Model Assessment for Insulin Resistance;
LDL, low-density lipoprotein; LV, left ventricular; mr-proANP, mid-regional pro-atrial natriuretic protein; NEP, neprilysin; Ns, not signifi-
cant; OGTT, oral glucose tolerance test; PFRE/PFRA, early peak filling rate/atrial peak filling rate; RR, Riva-Roci; sys, systolic; VO2 max, max-
imum oxygen uptake during exercise testing.
Differences between groups were analysed by one-way ANOVA.
*P ≤ 0.05.
a
P < 0.1 compared with low tertile.
b
P < 0.1 compared with middle tertile with Bonferroni’s post hoc test without and with Bonferroni–Holm correction for multiple testing.
Data are mean ± SD.
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reductions in NEP were observed in subjects ingesting less fat
(P = 0.052) and more carbohydrates (P = 0.005) at baseline,
when correlating food consumption before the study and
NEP reduction after 6 month independent of dietary group
(data not shown). The data also suggest a role of food fat
content in the regulation of plasma NEP levels.
In 51 participants of in which genetic analyses were avail-
able, the contribution of the SNPs rs9827586 and rs701109
located in the NEP locus to soluble NEP levels at baseline
was analysed. The SNPs were previously reported to affect
soluble NEP levels.13 In our cohort, minor allele carriers of
both rs9827586 (β = 0.53 ± 0.23, P < 0.0001) and rs701109
(β = 0.43 ± 0.22, P = 0.0016) showed higher soluble NEP
concentrations at baseline. This association remained valid
after adjustment for sex and age (rs9827586: P = 0.0002;
rs701109: P = 0.0017). Minor allele carriers of rs9827586
responded with a larger reduction in NEP (P = 0.0048), while
minor allele carriers of rs701109 showed only a tendency
(P = 0.059).
Conclusion
We conclude that weight loss with a low-calorie low-fat die-
tary intervention reduces soluble NEP concentrations and
SAT NEP mRNA expression in overweight to obese humans.
Our findings are in line with the notion that soluble NEP
levels are controlled by the nutritional state. In mice, weight
reduction reduced NEP levels, whereas a high-fat diet in-
creased NEP concentrations in visceral adipose tissue as well
as plasma.17 In parallel, human subjects with obesity have
been reported to have higher NEP levels correlating positively
with their body mass index.17,18 Previous data have shown
that NEP is expressed on mature adipocytes and also released
by them in a soluble form.17,19 Furthermore NEP promotes
adipogenesis, leading to a positive feedback loop, promoting
obesity.17 Yet, in our study, we did not observe a correlation
between body mass index, fat mass, and soluble NEP or NEP
mRNA. However, we did observe a positive correlation be-
tween soluble NEP and intramyocellular lipid content in skel-
etal muscle of our obese patients at baseline, which is in line
with our previously shown data that NPs, which are
inactivated by NEP, increase mitochondrial metabolism in
skeletal muscle and induce lipid oxidation.20,21 Our study
has limitations. It includes only overweight to obese partici-
pants, and the dietary intervention of 6 months is relatively
short. Furthermore, we cannot exclude that our sample size,
especially in the dietary subgroups, might have hindered de-
tection of smaller effects. Therefore, larger studies in addi-
tional patient populations are needed to test transferability
of the results to the general population.
Nevertheless, given the recent results of the PARADIGM
trial showing that inhibiting NEP in patients with HF with
reduced ejection fraction improves overall survival,9 nutri-
tional strategies to reduce NEP may also contribute to a
Figure 1 Soluble plasma neprilysin (NEP) and NEP mRNA expression in adipose tissue at baseline and after diet. (A) Soluble plasma NEP was measured
with ELISA (R&D Systems, Minneapolis, MN, USA) at baseline and after diet (n = 63). (B) Soluble plasma NEP at baseline and after low-fat diet (n = 36).
(C) Relative NEP mRNA expression at baseline and after diet divided in low-carbohydrate (n = 29) and low-fat diet (n = 34).
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better outcome in these patients and contribute to the ben-
eficial effect of weight loss on glucose control and cardiac
function.
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